Causal associations of tea consumption on risk of pancreatic adenocarcinoma and the mediating role of vascular endothelial growth factor D levels

Yonghao Ouyang[1]*[†], Beini Zhou[2†], Lihua Chu[3], Xin Chen[4], Qiang Hao[1] and Jiajia Lei[5]

[1]Research Institute of General Surgery, Jinling Hospital, Nanjing 210000, People's Republic of China
[2]Jiangxi Modern polytechnic college, Nanchang 330000, People's Republic of China
[3]Jinggangshan University, Ji'an 3343000, People's Republic of China
[4]Jiangxi University Of Traditional Chinese Medicine, Nanchang 330000, People's Republic of China
[5]College of Food Science & Project Engineering, Wuhan Polytechnic University, Wuhan 430023, People's Republic of China

Abstract

Tea is one of the most widely consumed beverages in the world. However, the association between tea and risk of pancreatic adenocarcinoma remains controversial. This study aimed to investigate the causal relationship between tea consumption and risk of pancreatic adenocarcinoma and to explore their mediating effects. The two-sample Mendelian randomisation (MR) analysis showed an inverse causal relationship between tea intake and pancreatic adenocarcinoma (OR: 0·111 (0·02, 0·85), $P < 0.04$). To examine the mediating effects, we explored the potential mechanisms by which tea intake reduces the risk of pancreatic adenocarcinoma. Based on the oral bioavailability and drug-like properties in Traditional Chinese Medicine Systems Pharmacology database, we selected the main active ingredients of tea. We screened out the fifteen representative targeted genes by Pharmmapper database, and the gene ontology enrichment analysis showed that these targeted genes were related to vascular endothelial growth factor (VEGF) pathway. The two-step MR analysis of results showed that only VEGF-D played a mediating role, with a mediation ratio of 0·230 (0·066, 0·394). In conclusion, the findings suggest that VEGF-D mediates the effect of tea intake on the risk of pancreatic adenocarcinoma.

Keywords: Mendelian randomisation: Tea consumption: Vascular endothelial growth factor: Pancreatic adenocarcinoma: Mediation

Pancreatic adenocarcinoma is a highly malignant tumours of the digestive system with an extremely poor prognosis and an average 5-year survival rate of approximately 10 %[1,2]. As one of the leading causes of cancer death worldwide, the incidence of pancreatic adenocarcinoma has increased approximately twice than in 1996[3,4]. It is predicted that by 2030, pancreatic adenocarcinoma will surpass breast, prostate and colorectal cancer as the second leading cause of cancer-related death in the USA[5]. Therefore, it is critical to prevent pancreatic adenocarcinoma.

Tea is one of the most widely consumed beverages in the world. Tea polyphenols (mainly including epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG) and epicallocatechin gallate (EGCG)) are the main components of tea that are effective against cancer[6]. Experimental studies have shown that tea is able to exert anticancer effects through antioxidant activity[7,8], cell cycle regulation[9–11], the inhibition of receptor tyrosine kinase pathway, immune system modulation and control of epigenetic modification, and others[12]. Epidemiological studies have found that tea intake reduces the risk of developing a variety of malignant tumours (such as liver cancer, colon cancer, oral cavity cancer, and oesophageal cancer)[13–15]. Tea extract may inhibit pancreatic adenocarcinoma through multiple pathways in most laboratory studies[16]. However, epidemiological studies remain controversial, and most of the meta-analysis results do not support the preventive effect of tea on pancreatic adenocarcinoma[17,18]. Blasiak *et al.* found that green tea extract decreased the levels of AP-1 transcription factor subunits and inhibited the VEGF-A mRNA levels[19]. Yang *et al.* found that EGCG treatment targeted HIF-1α and thereby suppressed VEGF-A activation[20]. Shimizu *et al.* suggested that EGCG

---

might inhibit the activation of the VEGF/VEGFR axis by inhibiting the expression of HIF-1α and several major growth factors[21].

Angiogenesis is a crucial process for tumour survival[22]. Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) are able to promote tumorigenesis by multiple pathways, such as inhibiting the tumour immune microenvironment and promoting tumour angiogenesis[21–24]. In pancreatic cancer, VEGF is able to act as a common pathway for multiple mechanisms to promote pancreatic carcinogenesis[25–27].

Traditional epidemiological studies are often biased due to the presence of multiple confounding factors. Mendelian randomisation (MR) analyses used genetic variation associated with risk factors as instrumental variables (IV) to assess whether there is a causal effect or whether there is a spurious association on disease outcome due to reverse causality in an observational setting[28]. Therefore, this study investigated the causal relationship between tea intake and pancreatic adenocarcinoma risk through a two-sample study and further explored mediating effect by two-step MR analysis.

Materials and methods

Data collection

The tea intake-related dataset (ukb-b-6066) which included 9 851 867 SNP and 447 485 individual samples was downloaded from UK Biobank. The mean and standard deviation values for the dataset were 3·49631 and 2·84 255 cup/d, respectively. Types of tea mainly include black tea and green tea. The data pertaining to tea intake were sourced from questionnaires, which contained inquiry 'How many cups of tea do you drink each day? (Include black and green tea)' with a range of 0–99 cups. Participants were instructed to provide their average intake over the past year. The pancreatic adenocarcinoma-related dataset (bbj-a-140) which included 8 885 075 SNP and 196 187 individual samples was downloaded from Biobank Japan. The VEGF-A (prot-b-22) and VEGF-D (prot-b-65) were obtained from the genome-wide association studies data determined by Folkersen L *et al.*[29] These datasets included 5 270 646 SNP and 3394 individual samples of European. The VEGF-A isoform 121 (prot-a-3197), VEGF-C (prot-a-3199), VEGFR-2 (prot-a-1622) and VEGFR-3 (prot-a-1129) were obtained from the genome-wide association studies data determined by Sun BB *et al.*[30] The flow chart of our study and the methodology with relation to the overall exposure–disease association and the mediating factors is shown in Fig. 1.

Selection of instrumental variables

The IV in this study was selected by the following criteria: (1) IV were strongly correlated with the exposure: we used the '$P < 5e$-08' of the correlation as the criterion for the SNP selection. If the number of SNP IV did not meet the analysis requirements, the standard was relaxed to '$P < 1e$-05' based on previous research experience[31,32]. (2) Exclusion of IV with linkage disequilibrium: the criteria was 'linkage disequilibrium (LD) r2 < 0·001 within a 10 000 kb distance'. (3) Exclusion of IV associated with

confounding factors: we removed SNP associated with confounding factors according to Phenoscanner (http://www.phenoscanner.medschl.cam.ac.uk/). (4) Exclusion of weak IV with F-value < 10 (F-value indicates the association strength magnitude, and the calculation formula: $F = (N-2) * (2 * ((beta)^2) * eaf * (1-eaf))/(1-(2 * ((beta)^2) * eaf * (1-eaf))$, beta: the effect size; eaf: the effect allele frequency).

Identifying potential mediator

Fig. 1(a) shows that mediators were selected for consideration in analysis. By TCMSP database (https://old.tcmsp-e.com/tcmsp.php), we obtained oral bioavailability (OB) and drug-likeness (DL) for the main ingredients of tea (EC, EGC, ECG and EGCG). 'OB $\geq$ 30 %' and 'DL $\geq$ 0·18' were the criterion for active ingredients of the tea.

We obtained the structure model of the main active ingredients of the tea by Pubchem database (https://pubchem.ncbi.nlm.nih.gov/). According to the structure model of the main active ingredients of the tea, we predicted the targeted genes by Pharmmapper database (http://lilab-ecust.cn/pharmmapper/index.html).

Through the gene ontology (GO) enrichment analysis, we explored the functions of targeted genes. Based on the results of GO enrichment analysis, we predicted the potential mediator.

Analysis methods

In this study, we used five MR analysis methods (MR-Egger, Weighted median, Inverse variance weighted (IVW), Simple mode and Weighted mode) to determine the relationship between exposure and outcome. IVW was considered as the main method of MR in the study and through multiple methods to verify the consistency of the results[33]. MR-Egger and IVW of Cochran Q assess heterogeneity. The intercept of MR-Egger regression is to appraise for pleiotropy. Leave-one-out method determined that the causal relationship between exposure and outcome was not affected by a single SNP. All the analyses were completed using R 4.1.1 software, and the program package adopted included 'TwoSampleMR', 'gwasglue' and 'MRPRESSO'. The '$P < 0·05$' was considered statistically significant.

Results

The causal effect of tea consumption on pancreatic adenocarcinoma

Using the ukb-b-6066 dataset, we obtained 4022 SNP that are strongly related to tea consumption ($P < 5e$-08). After excluding SNP with linkage disequilibrium, forty-one SNP were remained. Subsequently, we eliminated nine SNP (rs1453548, rs2472297, rs9302428, rs132904, rs10741694, rs9937354, rs4808940, rs57631352 and rs11587444) associated with confounding factors (diabetes, smoke and anticancer immunisation). Due to the presence of palindromic sequences, five SNP (rs11164870, rs2273447, rs2783129, rs56348300 and rs713598) were also removed. According to Poisson test, nine SNP (rs2351187, rs1481012, rs17245213, rs17576658, rs2117137, rs2478875, rs72797284, rs12591786 and rs34619) which are significant

(a)

(b)

Fig. 1. Flow charts: (a) flow chart of the study procedures; (b) flow chart of the two-step Mendelian randomisation analysis. Step 1: Genetic variant of tea intake is used as an instrument for the exposure of tea intake to estimate the causal impact of the exposure on mediators (identified by pharmacological analysis) of the association between the tea intake and the risk of pancreatic adenocarcinoma; step 2: Genetic variant of mediators is used as an instrument for the mediators to establish the causal impact of the mediators on the risk of pancreatic adenocarcinoma (causal effect of tea intake on the risk of pancreatic adenocarcinoma (total effects) = beta0; causal effect of tea intake on the mediators = beta1; causal effect of the mediators on the risk of pancreatic adenocarcinoma = beta2; mediating effects = beta1 × beta2; direct effects = beta0-beta1 × beta2). MR, Mendelian randomisation; GO, gene ontology.

different between ukb-b-6066 and bbj-a-140 were additionally deleted ($P < 0.05$). Finally, we selected sixteen SNP as IV for subsequent two-sample MR analysis (effect of tea consumption on pancreatic adenocarcinoma).

The results of two-sample MR analysis showed that genetically predicted increased tea consumption was associated with a decreased risk of pancreatic adenocarcinoma (IVW: OR: 0.111 (0.014, 0.853), $P = 0.033$, Fig. 2(a)). The results of five methods of MR analysis (MR-Egger: OR: 0.493 (0.003, 77.037);

Weighted median: OR: 0.133 (0.008, 2.129); IVW: OR: 0.111 (0.014, 0.853); Simple mode: OR: 0.036 (0.001, 2.430); Weighted mode: OR: 0.115 (0.007, 1.846)) are consistent (Fig. 2(a)). The effect size of each SNP of tea consumption on pancreatic adenocarcinoma is shown in Fig. 2(b). Besides, the Cochran's Q statistics of MR-Egger and IVW (MR-Egger: Q = 15.057, $P = 0.374$; IVW: Q = 15.490, $P = 0.417$) did not show a significant heterogeneity. There was no significant intercept (intercept = −0.032; SE = 0.050. $P = 0.536$), indicating the absence of

Fig. 2. The causal effect of tea consumption on pancreatic adenocarcinoma: (a) genetically predicted increased tea consumption was associated with a decreased risk of pancreatic adenocarcinoma; (b) the effect size of each SNP for tea consumption on pancreatic adenocarcinoma; (c) there was statistically no directional pleiotropy; and (d) there was no apparent outlying SNP.

Table 1. The OB and DL of main tea polyphenols

Tea polyphenols	OB	DL
ent-Epicatechin	48·96	0·24
(-)-Epicatechin	28·93	0·24
Epigallocatechin	24·18	0·27
Epicatechin gallate	17·89	0·75
L-Epicatechin gallate	3·01	0·75
(-)-Epigallocatechin-3-gallate	55·09	0·77

OB, oral bioavailability; DL, drug-likeness.

directional pleiotropy in statistics (Fig. 2(c)). We iteratively removed one SNP and performed IVW using the remaining SNP and did not observe significantly outlying SNP (Fig. 2(d)).

Level of vascular endothelial growth factor and vascular endothelial growth factor receptor were potential mediator

To explore the potential mediators, we used pharmacological analysis to predict the targeted gene functions of the main active components in tea. By using the TCMSP database, we obtained the OB and DL values for EC, EGC, and ECG and EGCG (Table 1). The ent-Epicatechin and (-) -Epigallocatechin-3-gallate were used as the main active components of tea for the next analysis (OB > 30 %, DL > 0·18). Through the Pubchem database, we obtained the molecular structure of ent-Epicatechin and (-) -Epigallocatechin-3-gallate. We predicted the targeted genes of ent-Epicatechin and (-) -Epigallocatechin-3-gallate by Pharmmapper database, and then a total of seventy-three targeted genes for ent-Epicatechin and seventy-one targeted genes for (-) -Epigallocatechin-3-gallate were obtained. We identified a total of fifteen representative targeted genes (ACADM, AZGP1, CCNE1, GAN, NAT1, NR3C2, PDK2, PRKD2, RARG, RUVBL1, SPEN, SUOX, USP19, VEGFA and VEGFB) which are the targeted genes for both ent-Epicatechin and (-) -Epigallocatechin-3-gallate (Fig. 3(a)). Using the GEPIA database (the method is one-way ANOVA), we performed a differential analysis of the expression of these genes in pancreatic adenocarcinoma. The results showed that all of these fifteen representative targeted genes were differentially expressed


Fig. 3. Pharmacological analysis to predict the function of targeted genes of main active components of tea: (a) fifteen representative targeted genes were determined; (b) the results of gene ontology (GO) enrichment analysis showed that these fifteen representative targeted genes enriched in vascular endothelial growth factor (VEGF) pathway.

Exposure	Meidator	Methods	nSNP	OR	pvalue	
	VEGF					
Tea consumption	VEGF-A	MR-Egger	17	1·428[0·237-8·606]	0·703	
Tea consumption	VEGF-A	Weighted median	17	0·983[0·344-2·807]	0·975	
Tea consumption	VEGF-A	Inverse variance weighted	17	0·847[0·395-1·816]	0·670	
Tea consumption	VEGF-A	Simple mode	17	1·213[0·193-7·618]	0·840	
Tea consumption	VEGF-A	Weighted mode	17	1·062[0·350-3·221]	0·917	
Tea consumption	VEGF-A (isoform 121)	MR-Egger	26	0·989[0·205-4·774]	0·989	
Tea consumption	VEGF-A (isoform 121)	Weighted median	26	1·777[0·750-4·21]	0·191	
Tea consumption	VEGF-A (isoform 121)	Inverse variance weighted	26	1·352[0·743-2·459]	0·323	
Tea consumption	VEGF-A (isoform 121)	Simple mode	26	2·473[0·562-10·887]	0·242	
Tea consumption	VEGF-A (isoform 121)	Weighted mode	26	2·430[0·884-6·999]	0·112	
Tea consumption	VEGF-C	MR-Egger	26	0·515[0·107-2·484]	0·416	
Tea consumption	VEGF-C	Weighted median	26	1·068[0·430-2·651]	0·888	
Tea consumption	VEGF-C	Inverse variance weighted	26	1·139[0·627-2·072]	0·669	
Tea consumption	VEGF-C	Simple mode	26	1·126[0·217-5·830]	0·889	
Tea consumption	VEGF-C	Weighted mode	26	1·182[0·373-3·741]	0·778	
Tea consumption	VEGF-D	MR-Egger	17	0·550[0·091-3·311]	0·523	
Tea consumption	VEGF-D	Weighted median	17	0·489[0·171-1·401]	0·183	
Tea consumption	VEGF-D	Inverse variance weighted	17	0·435[0·203-0·931]	0·032	
Tea consumption	VEGF-D	Simple mode	17	0·481[0·095-2·439]	0·39	
Tea consumption	VEGF-D	Weighted mode	17	0·491[0·168-1·439]	0·213	
	VEGFR					
Tea consumption	VEGFR-2	MR-Egger	26	1·420[0·274-7·357]	0·680	
Tea consumption	VEGFR-2	Weighted median	26	0·813[0·319-2·073]	0·665	
Tea consumption	VEGFR-2	Inverse variance weighted	26	0·701[0·376-1·307]	0·264	
Tea consumption	VEGFR-2	Simple mode	26	1·396[0·255-7·657]	0·704	
Tea consumption	VEGFR-2	Weighted mode	26	0·897[0·288-2·799]	0·853	
Tea consumption	VEGFR-3	MR-Egger	26	0·471[0·072-3·079]	0·439	
Tea consumption	VEGFR-3	Weighted median	26	0·388[0·159-0·947]	0·038	
Tea consumption	VEGFR-3	Inverse variance weighted	26	0·562[0·279-1·131]	0·106	
Tea consumption	VEGFR-3	Simple mode	26	0·452[0·091-2·237]	0·339	
Tea consumption	VEGFR-3	Weighted mode	26	0·384[0·138-1·073]	0·080	

Forest plot

Fig. 4. The causal effect of tea consumption on VEGF and VEGFR. VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

in pancreatic adenocarcinoma ($P < 0.05$, online Supplementary Fig. S1). Subsequently, we performed a GO enrichment analysis on these fifteen representative targeted genes. The results of GO enrichment analysis showed that these fifteen representative targeted genes were enriched in VEGF pathway (Fig. 3(b)). Therefore, we speculated that the VEGF and VEGFR were potential mediators.

The causal effect of tea consumption on vascular endothelial growth factor and vascular endothelial growth factor receptor

Given the results of GO analysis of fifteen representative targeted genes for main active components of tea, we further explored the causal effects of tea consumption on VEGF and VEGFR (Fig. 4). The results of MR analysis showed that genetically predicted increased tea consumption was associated with a decreased level of VEGF-D (IVW: OR: 0·435 (0·203, 0·931), $P = 0.032$). The results of the five MR analysis methods (MR-Egger: OR: 0·550 (0·091, 3·311); Weighted median: OR: 0·489 (0·171, 1·401); IVW: OR: 0·435 (0·203, 0·931); Simple mode: OR: 0·481 (0·095, 2·439); Weighted mode: OR: 0·491 (0·168, 1·439))

are consistent. However, no causal association was observed between tea consumption and VEGF-A (IVW: OR: 0·847 (0·395, 1·816), $P = 0.670$), VEGF-A (isoform 121) (IVW: OR: 1·352 (0·743, 2·459), $P = 0.323$), VEGF-C (IVW: OR: 1·139 (0·627, 2·072), $P = 0.669$), VEGFR-2 (IVW: OR: 0·701 (0·376, 1·307), $P = 0.264$) and VEGFR-3 (IVW: OR: 0·562 (0·279, 1·131), $P = 0.106$). The effect size of each SNP for tea consumption on VEGF and VEGFR is shown in online Supplementary Fig. S2. The Cochran's Q statistics of MR-Egger and IVW did not show a significant heterogeneity (online Supplementary Table S1). The scatter plot showed that there was statistically no pleiotropy (online Supplementary Fig. S3). We iteratively removed one SNP and used the remaining SNP for inverse variance weighting, and no apparent outlying SNP was observed (online Supplementary Fig. S4).

The causal effect of VEGF-D on pancreatic adenocarcinoma

Due to the number of SNP IV was not meet the analysis requirements, we reset the correlative standard (between tea consumption and instrumental SNP) to '$P < 1e-05$'. We used five

Fig. 5. The causal effect of VEGF-D on pancreatic adenocarcinoma: (a) genetically predicted increased VEGF-D was associated with an increased risk of pancreatic adenocarcinoma; (b) the effect size of each SNP for VEGF-D on pancreatic adenocarcinoma; (c) there was statistically no directional pleiotropy; and (d) there was no apparent outlying SNP. VEGF, vascular endothelial growth factor.

MR analysis methods to determine the relationship between VEGF-D and pancreatic adenocarcinoma (Fig. 5(a)). The results of MR analysis showed that increased VEGF-D was associated with a reduced risk of pancreatic adenocarcinoma in genetic prediction (IVW: OR: 1·835 (1·109, 3·038), *P* = 0·018). The results of the five MR analysis methods (MR-Egger: OR: 1·558 (0·387, 6·278); Weighted median: OR: 1·522 (0·797, 2·907); IVW: OR: 1·835 (1·109, 3·038); Simple mode: OR: 1·966 (0·966, 4·000); Weighted mode: OR: 1·658 (0·810, 3·392)) are consistent. The effect size of each SNP for VEGF-D on pancreatic adenocarcinoma is shown in Fig. 5(b). Besides, the Cochran's Q statistics of MR-Egger and IVW (MR-Egger: Q = 1·805, *P* = 0·875; IVW: Q = 1·866, *P* = 0·932) did not show a significant heterogeneity. There was no significant intercept (intercept = 0·029; SE = 0·117. *P* = 0·815), indicating a statistical absence of directional pleiotropy (Fig. 5(c)). We iteratively removed one SNP and performed IVW using the remaining SNP, and no significant outlier SNP were observed (Fig. 5(d)).

Mediation proportion

Based on the MR analysis results, we used VEGF-D as the mediator and calculated the mediation proportion. The results showed that the mediating proportion was beta0-beta1 × beta2 = 0·230 (0·066–0·394).

Discussion

In this study, we found that in genetic prediction, increased tea consumption was associated with a decreased risk of pancreatic adenocarcinoma by the results of two-sample MR analysis based on genome-wide association studies data. The conclusion was consistent with the findings of case–control studies of Wang *et al.* and Liu *et al.*[34,35] Our results underscore the significance of tea consumption in the prevention of pancreatic adenocarcinoma and mediating effects of VEGF-D in this process, which provides novel insights for future investigations.

Then, we selected fifteen representative targeted genes (ACADM, AZGP1, CCNE1, GAN, NAT1, NR3C2, PDK2, PRKD2, RARG, RUVBL1, SPEN, SUOX, USP19, VEGFA and VEGFB) by pharmacological analysis. Differential analysis indicated that these fifteen genes were significantly different in pancreatic adenocarcinoma and normal pancreatic tissues. Previous studies have also showed a connection between these targeted genes and pancreatic adenocarcinoma[36–42].

We preliminarily predicted VEGF and VEGFR as potential mediators by GO enrichment analysis. Similarly, McMillan *et al.* and Shankar *et al.* showed that catechin can inhibit pancreatic cancer by inhibiting VEGF and VEGFR[9,43]. However, previous study only performed with experimental study in tumour cells or animal models. It is important and more realistic to validate the role of VEGF and VEGF in tea and pancreatic adenocarcinoma in epidemiological studies. The results of this study showed that VEGF and VEGFR may be the potential mediator in causal effect of tea consumption on pancreatic adenocarcinoma. Subsequently, we performed the two-step MR analysis to validate it and calculate the mediation proportion. The results of MR analysis showed that genetically predicted increased tea consumption was associated with a decreased level of VEGF-D. Mineva *et al.* and Rashidi *et al.* believed that EGCG suppresses VEGF by multiple pathways[44,45]. By using the Weighted median method, we found that the genetically predicted tea consumption was able to be associated with the decrease of VEGFR-3 (*P* < 0·05). Since heterogeneity and pleiotropy were not statistically considered in the results of this analysis, we believed that the IVW method is the priority choice method[46]. The results of IVW did not show a causal relationship between tea consumption and VEGFR-3. Subsequently, we explored the causal effect of VEGF-D on pancreatic adenocarcinoma by MR analysis. The results showed that genetically predicted level of VEGF-D is associated with pancreatic adenocarcinoma. This result is consistent with the findings of previous experimental studies mentioned above[9,43]. Therefore, our study found that genetically predicted increased tea consumption is associated with a reduced risk of pancreatic adenocarcinoma, with VEGF-D mediating 23 % effect of tea consumption on the risk of pancreatic adenocarcinoma.

The strengths of this study are as follows: (1) genome-wide association studies-based MR analysis was used in this study, which greatly controlled confounding factors; (2) this study combined pharmacological analysis and two-step MR analysis to explore the mediators between tea consumption and risk of pancreatic adenocarcinoma, which also strengthened the interpretability of the MR analysis results; and (3) the results were validated by applying multiple kinds of MR methods with different model assumptions, and the effects of outlier and pleiotropy were comprehensively assessed. Also, the consistency and reliability of study results were validated.

However, this study has some limitations: the limited reference annotated gene set failed to match all predicted target genes and thus may have result in part of targeted genes not included, which may lead us to ignore some other potential mediators.

In conclusion, combining MR analysis and pharmacological analysis, this study found that genetically predicted tea consumption was inversely associated with pancreatic adeno-carcinoma risk, 23 % of which was mediated by VEGF-D. However, more experimental studies and epidemiological studies are still needed to validate this conclusion.

Supplementary material

For supplementary material/s referred to in this article, please visit https://doi.org/10.1017/S0007114524002393

References

1. Lin QJ, Yang F, Jin C, et al. (2015) Current status and progress of pancreatic cancer in China. World J Gastroenterol 21, 7988–8003.
2. Chen WQ, Li H, Sun KX, et al. (2018) Report of cancer incidence and mortality in China, 2014. Zhonghua Zhong Liu Za Zhi 40, 5–13. Chinese.
3. Rawla P, Sunkara T & Gaduputi V (2019) Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 10, 10–27.
4. Siegel RL, Miller KD & Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68, 7–30.
5. Rahib L, Smith BD, Aizenberg R, et al. (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74, 2913–2921.
6. Farhan M (2022) Green Tea Catechins: nature's way of preventing and treating cancer. Int J Mol Sci 23, 10713.
7. Zheng LT, Ryu GM, Kwon BM, et al. (2008) Anti-inflammatory effects of catechols in lipopolysaccharide-stimulated microglia cells: inhibition of microglial neurotoxicity. Eur J Pharmacol 588, 106–113.
8. Lambert JD & Elias RJ (2010) The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys 501, 65–72.
9. Shankar S, Ganapathy S, Hingorani SR, et al. (2008) EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 13, 440–452.
10. Masuda M, Suzui M & Weinstein IB (2001) Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 7, 4220–4229.
11. Shimizu M, Deguchi A, Lim JT, et al. (2005) (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 11, 2735–2746.
12. Shirakami Y & Shimizu M (2018) Possible mechanisms of green tea and its constituents against cancer. Molecules 23, 2284.
13. Huang YQ, Lu X, Min H, et al. (2016) Green tea and liver cancer risk: a meta-analysis of prospective cohort studies in Asian populations. Nutrition 32, 3–8.
14. Su LJ & Arab L (2002) Tea consumption and the reduced risk of colon cancer – results from a national prospective cohort study. Public Health Nutr 5, 419–425.
15. Ren JS, Freedman ND, Kamangar F, et al. (2010) Tea, coffee, carbonated soft drinks and upper gastrointestinal tract cancer risk in a large United States prospective cohort study. Eur J Cancer 46, 1873–1881.
16. Suhail M, Rehan M, Tarique M, et al. (2023) Targeting a transcription factor NF-κB by green tea catechins using in silico and in vitro studies in pancreatic cancer. Front Nutr 9, 1078642.
17. Abe SK & Inoue M (2021) Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence. Eur J Clin Nutr 75, 865–876.
18. Wei J, Chen L & Zhu X (2014) Tea drinking and risk of pancreatic cancer. Chin Med J (Engl) 127, 3638–3644.
19. Blasiak J, Chojnacki J, Szczepanska J, et al. (2023) Epigallocatechin-3-Gallate, an active green tea component to support anti-VEGFA therapy in wet age-related macular degeneration. Nutrients 15, 3358.
20. Yang N & Li X (2022) Epigallocatechin gallate relieves asthmatic symptoms in mice by suppressing HIF-1α/VEGFA-mediated M2 skewing of macrophages. Biochem Pharmacol 202, 115112.
21. Shimizu M, Shirakami Y, Sakai H, et al. (2010) (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem Biol Interact 185, 247–252.
22. Shaw P, Dwivedi SKD, Bhattacharya R, et al. (2024) VEGF signaling: role in angiogenesis and beyond. Biochim Biophys Acta Rev Cancer 1879, 189079.
23. Kuo HY, Khan KA & Kerbel RS (2024) Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nat Rev Clin Oncol 21, 468–482.
24. Zhang R, Yao Y, Gao H, et al. (2024) Mechanisms of angiogenesis in tumour. Front Oncol 14, 1359069.
25. Hao S, Ji Y, Pan W, et al. (2023) Long non-coding RNA BANCR promotes pancreatic cancer lymphangiogenesis and lymphatic metastasis by regulating the HIF-1α/VEGF-C/VEGFR-3 pathway via miR-143–5p. Genes Dis 11, 101015.
26. Alabaş E & Ata Özçimen A (2024) The supression of migration and metastasis via inhibition of vascular endothelial growth factor in pancreatic adenocarcinoma cells applied Danusertib. Turk J Gastroenterol 35, 150–157.
27. Huang C, Li H, Xu Y, et al. (2024) BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. (published correction appears in Signal Transduct). Target Ther 9, 8.
28. Sekula P, Del Greco MF, Pattaro C, et al. (2016) Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol 27, 3253–3265.
29. Folkersen L, Fauman E, Sabater-Lleal M, et al. (2017) Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PloS Genet 13, e1006706.
30. Sun BB, Maranville JC, Peters JE, et al. (2018) Genomic atlas of the human plasma proteome. Nature 558, 73–79.
31. Liang X & Fan Y (2023) Bidirectional two-sample Mendelian randomization analysis reveals a causal effect of interleukin-18 levels on postherpetic neuralgia risk. Front Immunol 14, 1183378.
32. Wootton RE, Lawn RB, Millard LAC, et al. (2018) Evaluation of the causal effects between subjective wellbeing and cardiometabolic health: Mendelian randomisation study. BMJ 362, k3788.
33. Ma Z, Chen Q, Liu Z, et al. (2024) Genetically predicted inflammatory proteins and the risk of atrial fibrillation: a bidirectional Mendelian randomization study. Front Cardiovasc Med 11, 1375750.
34. Wang J, Zhang W, Sun L, et al. (2012) Green tea drinking and risk of pancreatic cancer: a large-scale, population-based case-control study in urban Shanghai. Cancer Epidemiol 36, e354–e358.
35. Liu SZ, Chen WQ, Wang N, et al. (2014) Dietary factors and risk of pancreatic cancer: a multi-centre case-control study in China. Asian Pac J Cancer Prev 15, 7947–7950.
36. Yang Y, Gu H, Zhang K, et al. (2023) Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. BMC Cancer 23, 789.
37. Kong B, Michalski CW, Hong X, et al. (2010) AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-β-mediated ERK signaling. Oncogene 29, 5146–5158.
38. Philip PA, Azar I, Xiu J, et al. (2022) Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res 28, 2704–2714.
39. Kang JJ, Liu IY, Wang MB, et al. (2016) A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer. Hum Genet 135, 675–684.
40. Zhang K, Gao L, Wu Y, et al. (2015) NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis. Int J Clin Exp Med 8, 9177–9191.

41. Zhang Z, Che X, Yang N, *et al.* (2017) miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. *Biomed Pharmacother* **96**, 1341–1348.

42. Costache MI, Ioana M, Iordache S, *et al.* (2015) VEGF expression in pancreatic cancer and other malignancies: a review of the literature. *Rom J Intern Med* **53**, 199–208.

43. McMillan B, Riggs DR, Jackson BJ, *et al.* (2007) Dietary influence on pancreatic cancer growth by catechin and inositol hexaphosphate. *J Surg Res* **141**, 115–119.

44. Mineva ND, Paulson KE, Naber SP, *et al.* (2013) Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells. *PLoS One* **8**, e73464.

45. Rashidi B, Malekzadeh M, Goodarzi M, *et al.* (2017) Green tea and its anti-angiogenesis effects. *Biomed Pharmacother* **89**, 949–956.

46. Bowden J & Holmes MV (2019) Meta-analysis and Mendelian randomization: a review. *Res Synth Methods* **10**, 486–496.